Erratum: Dual orexin receptor antagonists - Promising agents in the treatment of sleep disorders (International Journal of Neuropsychopharmacology 17:1 DOI: 10.1017/S1461145713000552);Dual orexin receptor antagonists-promising agents in the treatment of sleep disorders

International Journal of Neuropsychopharmacology

Volumn 17, Issue 1, 2014, Pages 157-168

  Pałasz, Artur ^a   Lapray, Damien ^b   Peyron, Christelle ^c   Rojczyk Gołeȩbiewska, Ewa ^a   Skowronek, Rafał ^a   Markowski, Grzegorz ^d   Czajkowska, Beata ^e   Krzystanek, Marek ^a   Wiaderkiewicz, Ryszard ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b EPFL   (Switzerland)

^c UNIVERSITÉ LYON 1   (France)

^d UNIVERSITY OF SILESIA   (Poland)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Almorexant; DORAs; orexins; sleep disorders; suvorexant

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; ACTELION; ALMOREXANT; BENZODIAZEPINE DERIVATIVE; DUAL OREXIN RECEPTOR ANTAGONIST; FILOREXANT; OREXIN; OREXIN 1 RECEPTOR; OREXIN 2 RECEPTOR; PEPTIDE HORMONE RECEPTOR BLOCKING AGENT; SB 649868; SIMVASTATIN; SUVOREXANT; UNCLASSIFIED DRUG; ZOLPIDEM; (4-(5-CHLORO-1,3-BENZOXAZOL-2-YL)-7-METHYL-1,4-DIAZEPAN-1-YL)(5-METHYL-2-(2H-1,2,3-TRIAZOL-2-YL)PHENYL)METHANONE; (5-((5-FLUOROPYRIDIN-2-YLOXY)METHYL)-2-METHYLPIPERIDIN-1-YL)(5-METHYL-2-(PYRIMIDIN-2-YL)PHENYL)METHANONE; ACETAMIDE DERIVATIVE; AZEPINE DERIVATIVE; BENZOFURAN DERIVATIVE; ISOQUINOLINE DERIVATIVE; N-((1-((5-(4-FLUOROPHENYL)-2-METHYL-4-THIAZOLYL)CARBONYL)-2-PIPERIDINYL)METHYL)-4-BENZOFURANCARBOXAMIDE; OREXIN RECEPTOR; PIPERIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE; TRIAZOLE DERIVATIVE;

ALERTNESS; AREA UNDER THE CURVE; BLURRED VISION; BRAIN REGION; CATAPLEXY; COGNITIVE DEFECT; DAYTIME SOMNOLENCE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DEPENDENCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HEADACHE; HUMAN; HYPNAGOGIC HALLUCINATION; INNERVATION; INSOMNIA; LOCOMOTION; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN; OREXINERGIC INNERVATION; OREXINERGIC TRANSMISSION; PARASOMNIA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; REPEATED DRUG DOSE; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SLEEP DISORDER; SLEEP TIME; SLEEP WAKING CYCLE; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; DRUG EFFECTS; PHYSIOLOGY; SLEEP; SLEEP INITIATION AND MAINTENANCE DISORDERS; WAKEFULNESS;

ACETAMIDES; ANIMALS; AZEPINES; BENZOFURANS; HUMANS; ISOQUINOLINES; MODELS, BIOLOGICAL; OREXIN RECEPTORS; PIPERIDINES; PYRIMIDINES; SLEEP; SLEEP INITIATION AND MAINTENANCE DISORDERS; THIAZOLES; TRIAZOLES; WAKEFULNESS;

EID: 84888610809     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1093/ijnp/pyw005     Document Type: Erratum

References (75)

1. Adamantidis AR, Hang F, Aravanis AM, Deisseroth K, de Lecea L (2007) Neural substrates of awakening probed with optogenetic control of hypocretin neurons. Nature 450:420-424. (Pubitemid 350126754)
2. Bettica P, Squassante L, Zamuner S, Nucci G, Danker-Hopfe H, Ratti E (2012a) The orexin antagonist SB-649868 promotes and maintains sleep in men with primary insomnia. Sleep 35:1097-1104.
3. Bettica P, Squassante L, Groeger JA, Gennery B, Winsky-Sommerer R, Dijk DJ (2012b) Differential effects of a dual orexin receptor antagonist (SB-649868) and zolpidem on sleep initiation and consolidation, SWS, REM sleep, and EEG power spectra in a model of situational insomnia. Neuropsychopharmacology 37:1224-1233.
4. Bettica P, Nucci G, Pyke C, Squassante L, Zamuner S, Ratti E, Gomeni R, Alexander R (2012c) Phasei studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist. J Psychopharmacol 26:1058-1070.
5. Bonnavion P, de Lecea L (2010) Hypocretins in the control of sleep and wakefulness. Curr Neurol Neurosci Rep10:174-179.
6. Bourgin P, Huitrón-Résendiz S, Spier AD, Fabre V, Morte B, Criado JR, Sutcliffe JG, Henriksen SJ, de Lecea L (2000) Hypocretin-1 modulates rapid eye movement sleep through activation of locus coeruleus neurons. J Neurosci 20:7760-7765.
7. Brisbare-Roch C, Dingemanse J, Koberstein R, Hoever P, Aissaoui H, Flores S, Mueller C, Nayler O, van Gerven J, de Haas SL, Hess P, Qiu C, Buchmann S, Scherz M, Weller T, Fischli W, Clozel M, Jenck F (2007) Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med 13:150-155.
8. Brisbare-Roch C, Fischer C, Jenck F (2010) Effect of once-daily almorexant treatment for 6 weeks on the sleep-wake cycle of normal Wistar rats. Eur Neuropsychopharmacol 20 (Suppl.):253-254.
9. Carter ME, Brill J, Bonnavion P, Huguenard JR, Huerta R, de Lecea L (2012) Mechanism of hypocretin-mediated sleep-to wake transitions. Proc Natl Acad Sci USA 5: E2636-E2644.
10. Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C, Richardson JA, Williams SC, Xiong Y, Kisanuki Y, Fitch TE, Nakazato M, Hammer RE, Saper CB, Yanagisawa M (1999) Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98:437-451. (Pubitemid 29402482)
11. Coleman PJ, Cox CD, Roecker AJ (2011) Discovery of dual receptor antagonists (DORAs) for the treatment of insomnia. Curr Top Med Chem 11:696-725.
12. Coleman PJ, et al. (2012) Discovery of [(2R, 5R)-5-{[(5-fluoropyridin-2- yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl) phenyl]methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting properties. Chem Med Chem 7:415-424.
13. Cox CD et al. (2010) Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1, 3-benzoxazol-2-yl)-7-methyl-1, 4-diazepan-1-yl][5-methyl-2- (2H-1, 2, 3-triazol-2-yl) phenyl]methanone (MK-4305) for the treatment of insomnia. J Med Chem 53:5320-5332.
14. Cruz H, Hoever P, Hay J, Alessi F, Dingemanse J, van Gerven J (2010) Interaction study between almorexant, a dual orexin receptor antagonist, and desipramine in healthy male subjects. Eur Neuropsychopharmacol 20 (Suppl.):253.
15. de Lecea L, Kilduff TS, Peyron C, Gao X, Foye PE, Danielson PE, Fukuhara C, Battenberg EL, Gautvik VT, Bartlett FS II, Frankel WN, van den Pol AN, Bloom FE, Gautvik KM, Sutcliffe JG (1998) The hypocretins: hypothalamus-specific peptides with neuoroexcitatory activity. Proc Natl Acad Sci USA 95:322-327. (Pubitemid 28103952)
16. de Lecea L, Carter ME, Adamantidis A (2012) Shining light on wakefulness and arousal. Biol Psychiatry 71:1046-1052.
17. di Fabio R et al. (2011) Discovery process and pharmacological characterization of a novel dual orexin 1 and orexin 2 receptor antagonist useful for treatment of sleep disorders. Bioorg Med Chem Lett 21:5562-5567.
18. Fort P, Bassetti CL, Luppi PH (2009) Alternating vigilance states: new insights regarding neuronal networks and mechanisms. Eur J Neurosci 29:1741-1753.
19. Friess E, Tagaya H, Grethe C, Trachsel L, Holsboer F (2004) Acute cortisol administration promotes sleep intensity in man. Neuropsychopharmacology 29:598-604. (Pubitemid 38365937)
20. Galvao Mde L, Sinigaglia-Coimbra R, Kawakami SE, Tufik S, Suchecki D (2009) Paradoxical sleep deprivation activates hypothalamic nuclei that regulate food intake and stress response. Psychoneuroendocrinology 34:1176-1183.
21. Gerrard PA, Porter RA, Holland V, Massagrande M, Poffe A, Piccoli L, Bettica P, Corsi M, Hagan F, Ratti E (2009) Preclinical pharmacology of SB-649868: a novel orexin OX1/OX2 receptor antagonist possessing potent hypnotic activity in rodents and primates. Sleep 32:A42.
22. Gervasoni D, Peyron C, Rampon C, Barbagli B, Chouvet G, Urbain N, Fort P, Luppi PH (2000) Role and origin of the GABAergic innervation of dorsal raphe serotonergic neurons. J Neurosci 20:4217-4225. (Pubitemid 30365692)
23. Gvilia I, Xu F, McGinty D, Szymusiak R (2006) Homeostatic regulation of sleep: a role for preoptic area neurons. J Neurosci 26:9426-9433. (Pubitemid 44396855)
24. Hagan JJ et al. (1999) Orexin a activates locus coeruleus cell firing and increases arousal in the rat. Proc Natl Acad Sci USA 96:10911-10916. (Pubitemid 29442243)
25. Herring W, Snyder E, Budd K, Hutzelmann J, Snavely D, Liu K, Lines C, Roth T, Michelson D (2012) Orexin receptor antagonism for treatment of insomnia. A randomized clinical trial of suvorexant. Neurology 79:2265-2274.
26. Hoch M, Hoever P, Zisowsky J, Priestley A, Fleet D, Dingemanse J (2012) Absolute oral bioavailability of almorexant, a dual orexin receptor antagonist, in healthy human subjects. Pharmacology 89:53-57.
27. Hoever P, de Haas S, Winkler J, Schoemaker RC, Chiossi E, van Gerven J, Dingemanse J (2010) Orexin receptor antagonism, a new sleep-promoting paradigm: an ascending single-dose study with almorexant. Clin Pharmacol Ther 87:593-600.
28. Hoever P, de Haas S, Dorffner G, Chiossi E, van Gerven JM, Dingemanse J (2012a) Orexin receptor antagonism: an ascending multiple-dose study with almorexant. J Psychopharmacol 26:1071-1080.
29. Hoever P et al. (2012b) Orexin receptor antagonism, a new sleep-enabling paradigm: a proof-of-concept clinical trial. Clin Pharmacol Ther 91:957-985.
30. Hondo M, Furutani N, Yamasaki M, Watanabe M, Sakurai T (2012) Orexin neurons receive glycinergic innervations. PLoS One 6:e25076.
31. Ishizuka T, Murotani T, Yamatodani A (2012) Action of modafinil through histaminergic and orexinergic neurons. Vitam Horm 89:259-278.
32. Jara CO, Popp R, Zulley J, Hajak G, Geisler P (2011) Determinants of depressive symptoms in narcoleptic patients with and without cataplexy. J NervMent Dis 199:329-334.
33. Katayama S, Shigemi K, Cline MA, Furuse M (2010) Intracerebroventricular injection of orexin a stimulates monoamine metabolism but not HPA axis in neonatal chicks. Neurosci Lett 484:157-161.
34. Kukkonen J (2013) Physiology of the orexinergic/hypocretinergic system: a revisit in 2012. Am J Physiol Cell Physiol 304:C2-C32.
35. Kuru M, Ueta Y, Serino R, Nakazato M, Yamamoto Y, Shibuya I, Yamashita H (2000) Centrally administered orexin/hypocretin activates HPA axis in rats. Neuroreport 11:1977-1980. (Pubitemid 30429147)
36. Lattova Z, Keckeis M, Maurovich-Horvat E, Wetter TC, Wilde-Frenz J, Schuld A, Polmächer T (2011) The stress hormone system in various sleep disorders. J Psychiatr Res 45:1223-1228.
37. Lee J, Reddy MM, Kodadek T (2010) Discovery of an orexin receptor positive potentiator. Chem Sci 1:48-54.
38. Lu J, Bjorkum AA, Xu M, Gaus SE, Shiromani PJ, Saper CB (2002) Selective activation of the extended ventrolateral-preoptic nucleus during rapid eye movement sleep. J Neurosci 22:4568-4576. (Pubitemid 37465673)
39. Malherbe P, Borroni E, Pinard E, Wettstein JG, Knoflach F (2009) Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist: comparison with selective OX1 and OX2 antagonists. Mol Pharmacol 76:618-631.
40. Mang GM, Dürst T, Bürki H, Imobersteg S, Abramowski D, Schuepbach E, Hoyer D, Fendt M, Gee CE (2012) The dual orexin receptor antagonist almorexant induces sleep and decreases orexin-induced locomotion by blocking orexin 2 receptors. Sleep 35:1625-1635.
41. Marcus JN, Aschkenasi CJ, Lee CE, Chemelli RM, Saper CB, Yanagisawa M, Elmquist JK (2001) Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol 435:6-25. (Pubitemid 32448719)
42. Mileykovskiy BY, Kiyashchenko LI, Siegel JM (2005) Behavioral correlates of activity in identified hypocretin/orexin neurons. Neuron 46:787-798. (Pubitemid 40733133)
43. Murillo-Rodriguez E, Poot-Ake A, Arias-Carrion O, Pacheco-Pantoja E, del Fuente-Ortegon A, Arankowsky-Sandoval G (2011) The emerging role of the endocannabinoid system in the sleep-wake cycle modulation. Cent Nerv Syst Agents Med Chem 11:189-196.
44. Nishino S (2011) Hypothalamus, hypocretins/orexin and vigilance control. Handb Clin Neurol 99:765-782.
45. Nishino S, Mignot E (2011) Narcolepsy and cataplexy. Handb Clinical Neurol 99:783-814.
46. Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E (2000) Hypocretin (orexin) deficiency in human narcolepsy. Lancet 355:39-40. (Pubitemid 30072183)
47. Nollet M, Gaillard P, Minier F, Tanti A, Belzung C, Leman S (2011) Activation of orexin neurons in dorsomedial/perifornical hypothalamus and antidepressant reversal in a rodent model of depression. Neuropharmacology 61:336-346.
48. Nollet M, Gaillard P, Tanti A, Girault V, Belzung C, Leman S (2012) Neurogenesis-independent antidepressant-like effects on behavior and stress axis response of a dual orexin receptor antagonist in a rodent model of depression. Neuropsychopharmacology 37:2210-2221.
49. Pace-Schott EF, Hobson JA (2002) The neurobiology of sleep, genetics, cellular physiology and subcortical networks. Nat Rev Neurosci 3:591-605. (Pubitemid 135706668)
50. Peyron C, Tighe DK, van den Pol AN, de Lecea L, Heller HC, Sutcliffe JG, Kilduff TS (1998) Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 18:9996-10015. (Pubitemid 28543775)
51. Peyron C et al. (2000) A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 6:991-997.
52. Piccoli L, Micioni Di Bonaventura MV, Cifani C, Costantini VJ, Massagrande M, Montanari D, Martinelli P, Antolini M, Ciccocioppo R, Massi M, Merlo-Pich E, Di Fabio R, Corsi M (2012) Role of orexin-1 receptor mechanisms on compulsive food consumption in a model of binge eating in female rats. Neuropsychopharmacology 37:1999-2011.
53. Renzulli C, Nash M, Wright M, Thomas S, Zamuner S, Pellegatti M, Bettica P, Boyle G (2011) Disposition and metabolism of [14C]SB-649868 an orexin 1 and 2 receptor antagonist in humans. Drug Metab Dispos 39:215-227.
54. Roecker AJ, Coleman PJ (2008) Orexin receptor antagonists: medicinal chemistry and therapeutic potential. Curr Top Med Chem 8:977-987.
55. Russel SH, Small CJ, Dakin CL, Abbott CR, Morgan DG, Ghatei MA, Bloom SR (2001) The central effects of orexin a in the hypothalamic-pituitary-adrenal axis in vivo and in vitro in male rats. J Neuroendocrinol 13:561-566. (Pubitemid 32519559)
56. Sakurai T (2007) The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nat Rev Neurosci 8:171-181. (Pubitemid 46294664)
57. Sakurai T, Mieda M (2011) Connectomics of orexin-producing neurons: interface of systems of emotion, energy homeo-stasis and arousal. Trends Pharmacol Sci 32:451-462.
58. Sakurai T et al. (1998) Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92:573-585. (Pubitemid 28101119)
59. Sakurai T, Mieda M, Tsujino N (2010) The orexin system: role in the sleep/wake regulation. Ann NY Acad Sci 1200:149-161.
60. Santucci V, Storme JJ, Soubrie P, Le Fur G (1996) Arousal-enhancing properties of the CB1 cannabinoid receptor antagonist SR141716A in rats as assessed by electroencephalographic spectral and sleep-waking cycle analysis. Life Sci 58:P1303-P1310.
61. Saper CB, Chou TC, Scammell TE (2001) The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci 24:726-731. (Pubitemid 33097540)
62. Sasaki K, Suzuki M, Mieda M, Tsujino N, Roth B, Sakurai T (2011) Pharmacogenetic modulation of orexin neurons alters sleep/wakefulness states in mice. PLoS ONE 6:e20360.
63. Sherin JE, Elmquist JK, Torrealba F, Saper CB (1998) Innervation of histaminergic tuberomamillary neurons by GABAergic and galaninergic neurons in the ventrolateral preoptic nucleus of the rat. J Neurosci 18:4705-1721.
64. Spinazzi R, Andreis PG, Rossi GP, Nussdorfer GG (2006) Orexins in the regulation of the hypothalamic-pituitary-adrenal axis. Pharmacol Rev 58:46-57.
65. Steiner MA, Sciaretta C, Brisbare-Roch C, Strasser DS, Studer R, Jenck F (2012) Examining the role of endogenous orexins in hypothalamus-pituitary- adrenal axis endocrine function using transient dual orexin receptor antagonism in the rat. Psychoneuroendocrinology 38:560-571.
66. Steininger TL, Gong H, McGinty D, Szymusiak R (2001) Subregional organization of preoptic area/anterior hypothalamic projections to arousal-related monoaminergic cell groups. J Comp Neurol 429:638-653. (Pubitemid 32011859)
67. Sullivan SS, Guilleminault C (2009) Emerging drugs for insomnia: new frontiers for old and novel targets. Expert Opin Emerg Drugs 14:411-422.
68. Tafti M (2007) Reply to 'Promotion of sleep by targeting the orexin system in rats, dogs and humans'. Nat Med 13:525-526. (Pubitemid 46828467)
69. Trivedi P, Yu H, MacNeil VJ, Van der Ploeg LH, Guan XM (1998) Distribution of orexin receptor mRNA in the rat brain. FEBS Lett 438:71-75. (Pubitemid 28517837)
70. Tsunematsu T, Kilduff TS, Boyden ES, Takahashi S, Tominaga M, Yamanaka A (2011) Acute optogenetic silencing of orexin/hypocretin neurons induces slow-wave sleep in mice. J Neurosci 31:10529-10539.
71. Uschakov A, Gong H, McGinty D, Szymusiak R (2007) Efferent projections from the median preoptic nucleus to sleep-and arousal-regulatory nuclei in the rat brain. Neuroscience 150:104-120. (Pubitemid 350198695)
72. Vazquez-Palacios G, Retana-Marquez S, Bonilla-Jaime H, Veleazquez-Moctezuma H (2001) Further definition of the effect of corticosterone on the sleep-wake pattern in the male rat. Pharmacol Biochem Behav 70:305-310. (Pubitemid 33049941)
73. Winrow CJ, Gotter AL, Cox CD, Doran SM, Tannenbaum PL, Breslin MJ, Garson SL, Fox SV, Harrell CM, Stevens J, Reiss DR, Cui D, Coleman PJ, Renger JJ (2011) Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist. J Neurogenet 25:52-61.
74. Winrow CJ, Gotter AL, Cox CD, Tannenbaum PL, Garson SL, Doran SM, Breslin MJ, Schreier JD, Fox SV, Harrell CM, Stevens J, Reiss DR, Cui D, Coleman PJ, Renger JJ (2012) Pharmacological characterization of MK-6096-a dual orexin receptor antagonist for insomnia. Neuropharmacology 62:978-987.
75. Yamanaka A, Muraki Y, Tsujino N, Goto K, Sakurai T (2003) Regulation of orexin neurons by the monoaminergic and cholinergic systems. Biochem Biophys Res Commun 303:120-129. (Pubitemid 36338216)